Lower @entity5363 predicts angiographic impaired reperfusion and mortality in ST-elevation XXXX .

@entity5363 @entity583 @entity1
AIMS: @entity5363 is an anti-inflammatory negative acute-phase glycoprotein, synthesized by the liver. In this study, we aimed to investigate the effects of admission @entity5363 levels on coronary and myocardial blood flow and short- and long-term prognosis in @entity583 ( @entity583 ) @entity1 undergoing primary percutaneous coronary intervention. METHODS AND RESULTS: One hundred eighty consecutive @entity1 admitted with diagnosis of @entity583 and 55 healthy age- and sex-matched volunteer controls were enrolled in the study. @entity1 with @entity583 were divided into 2 groups in respect to thrombolysis in @entity583 myocardial perfusion grade after primary PCI: with thrombolysis in @entity583 myocardial perfusion grade 0-1-2 and thrombolysis in @entity583 myocardial perfusion grade 3. Serum levels of @entity5363 were lower in @entity1 with @entity583 than in the healthy group subjects. In-hospital and 1-year deaths were significantly higher in @entity1 from the abnormal perfusion group. In-hospital major adverse cardiac event (MACE) and 1-year follow-up MACE also were significantly higher in @entity1 from the abnormal perfusion group. The receiver-operating characteristic analysis indicated an optimal cut point of less than 200  g/mL, which detects 1-year mortality with a negative predictive value of 95%. The 1-year mortality rate and 1-year MACE were significantly higher in @entity1 with low @entity5363 level as compared with those with high @entity5363 level. CONCLUSIONS: Because low-admission @entity5363 levels are associated with impaired coronary flow in @entity583 @entity1 undergoing primary percutaneous coronary intervention, admission @entity5363 level detection may be helpful in identifying the @entity1 at a greater risk of poor coronary blood flow and worse short- and long-term prognosis.
